Group 1 - XPeng Motors will officially change its name to XPeng Group starting April 1, 2026, while the English name "XPeng Inc." remains unchanged. This name change does not affect the rights of shareholders [1] - The name change signifies XPeng's broader vision, which includes not only selling new cars globally but also technology licensing, Robotaxi, humanoid robots, and flying cars in the low-altitude economy sector. This strategy differentiates XPeng from other automakers and showcases its resilience [4] Group 2 - Changan Automobile's factory in Brazil has officially commenced production, with the first models being Changan UNI-T and Avita 11 [5] - The launch of the Brazilian factory represents a significant milestone for the Chinese automotive industry, marking the full-chain export of "R&D-production-service." Changan aims to reshape the global competitive landscape through localized manufacturing and ecosystem integration [7] Group 3 - BYD reported a revenue of 804 billion yuan for the year 2025, reflecting a year-on-year growth of 3.46%. Revenue from automotive and related industries reached 648.6 billion yuan, up 5.06%, with a net profit attributable to shareholders of 32.6 billion yuan and R&D investment of 63.4 billion yuan [8] - BYD's continuous investment in R&D has solidified its position as the global leader in new energy vehicle sales. In 2025, its high-end brands, including Yangwang, Tengshi, and Fangchengbao, collectively sold nearly 400,000 units, marking a 109% increase. The Yangwang U9X became the fastest globally, and BYD introduced the second-generation blade battery and fast-charging technology this year [11]

来源：环球网 摘要：作为扎根北京大兴"中国药谷"的创新药企代表，百奥赛图凭借自主研发的双引擎技术平台，在全 人抗体药物研发领域实现全球领先。公司已构建覆盖1000余个靶点、超百万条全人抗体序列体系，并开 发1700余种人源化疾病模型，为双抗、ADC、细胞治疗等前沿疗法提供高确定性研发支撑。立足北 京、布局全球，百奥赛图在美欧多地设立分支机构，2025年上半年海外业务占比近70%，营收同比增长 超50%，实现扭亏为盈。依托大兴生物医药基地"全链条出海"服务体系，公司加速技术输出与国际合 作，已达成280余项抗体授权合作，合作伙伴包括7家全球Top20药企，彰显"北京研发"的全球影响力。 关键词：中国药谷；全链条出海；药物研发；百奥赛图； 案例正文： 作为首都生物医药产业创新发展的标杆企业，扎根大兴生物医药产业基地的百奥赛图（北京）医药科技 股份有限公司，凭借全球领先的技术平台、高效的新药研发赋能体系和持续深化的国际布局，在全人抗 体药物研发领域不断突破，不仅为全球创新药产业注入 "北京力量"，更成为首都生命健康产业创新发 展的重要引擎。 在评价体系方面，自2014年起，百奥赛图率先构建全球规模领先的靶点人源化小 ...